

Preparing people to lead extraordinary lives


# GLYCEMIC INDICES AND RELATED BIOMARKERS IN PULMONARY EMBOLISM

Roumika Patil





## BACKGROUND ON PULMONARY EMBOLISM



- PE, also known as pulmonary embolism, is the blockage of pulmonary arteries in the lungs by a blood clot. This is often caused by an embolus that has traveled up to the lungs.
- Affects between 60-70 for every 100,000 in the US today
- Symptoms may include chest pain, fatigue, weakness, and shortness of breath





# AIM/PURPOSE

- To analyze the correlation between inflammatory and glycemic biomarkers and thrombosis
- To assess the variance of D-Dimer, CRP, PAI-1, tPA, TAFI, vWF, and endogenous GAGs compared with a control population





# MATERIALS/METHODS

- Whole blood samples were collected from patients with confirmed diagnosis of PE
- Control Human Plasma (CHP) were obtained from commercially available source (George King Biomedical Center).
- Samples were processed through centrifuge to achieve platelet poor plasma and then stored at 70 degrees Celsius.
- Samples were analyzed using sandwich ELISA and Heparin Red methods
- Concentrations of biomarkers were statistically analyzed using Excel, GraphPad Prism, and IBM SPSS.





# **HYPOTHESIS**

Pulmonary embolism patients will have significant associations with inflammatory and glycemic biomarkers when compared to a control population






# **D-DIMER ANALYSIS**





# **BACKGROUND ON D-DIMER**



## Structure

- Small protein fragment consisting of  $\alpha$ ,  $\beta$ , and  $\gamma$  peptide chains

## Production

- Made when blood clots dissolve


## Correlation to PE

 High D-Dimer levels suggest some sort of blood clotting condition





# **D-DIMER RESULTS**




N= 87	N= 115


Percentiles (N = 87)	PE Patients	Control Plasma
25%	2814.66	4.65
50%	4855.61	126.17
75%	9543.49	368.41

Percentiles (N = 115)	PE Patients	Control Plasma
25%	2835.27	4.65
50%	4410.04	126.17
75%	9233.37	369.09



# **D-DIMER RESULTS**





N= 115






# **CRP ANALYSIS**





# **BACKGROUND ON CRP**



#### Structure

 cyclic pentameric protein comprised of five identical non-covalently attached subunits

## **Function**

 assist in complement binding to foreign and damaged cells


## Correlation to PE


- High levels of CRP indicate acute inflammation





# **CRP RESULTS**






Percentiles (N = 87)	PE Patient	Control Plasma
25%	12.08	0.00
50%	13.26	0.11
75%	16.77	0.74


Percentiles (N = 115)	PE Patient	Control Plasma
25%	12.13	0.00
50%	13.42	0.07
75%	16.90	0.64



# **CRP RESULTS**














## PAI-1 ANALYSIS





## **BACKGROUND ON PAI-1**



#### Structure

 a single chain glycoprotein member of the superfamily of serine-protease inhibitors

#### **Function**

 protein blocks (inhibits) the action of other proteins called plasminogen activators, which promote dissolution of clots


#### Correlation to PE


High levels promote clotting





# **PAI-1 RESULTS**







Percentiles (N = 87)	PE patient	Control plasma
25%	32.30	1.70
50%	49.01	4.96
75%	66.44	12.86

Percentiles (N = 115)	PE patient	Control plasma
25%	32.30	1.93
50%	48.82	5.23
75%	66.31	16.46



# **PAI-1 RESULTS**










# TPA ANALYSIS





## **BACKGROUND ON TPA**



## Structure

 Is composed of two chains; heavy Achain and light B-chain

## **Function**

 Catalyzes the conversion of plasminogen to plasmin


## Correlation to PE

 Low tPA levels are associated with hypercoagulable states






# **TPA RESULTS**








N= 115


Percentiles (N = 87)	PE Patient	Control Plasma
25%	6.10	1.64
50%	9.74	3.03
75%	16.58	4.07

Percentiles (N = 115)	PE Patient	Control Plasma
25%	6.06	1.78
50%	11.11	3.37
75%	16.49	4.27 HROMBOS



# **TPA RESULTS**












# TAFI ANALYSIS





## **BACKGROUND ON TAFI**



## Production

- Glycoprotein secreted by the liver

#### **Function**

 Suppresses fibrinolysis by removing certain residues from fibrin clots


## Correlation to PE

High levels of TAFI are associated with high VTE incidence






# **TAFI RESULTS**



N= 87




N= 115


Percentiles (N = 87)	PE patient	Control plasma
25%	90.05	66.85
50%	97.85	83.11
75%	109.47	99.65

Percentiles (N = 115)	PE patient	Control plasma
25%	90.74	76.48
50%	98.30	92.31
75%	110.87	103.91



# **TAFI RESULTS**





N= 115






# **VWF ANALYSIS**





## **BACKGROUND ON VWF**



## Structure

 Large multimeric glycoprotein present in plasma

## **Function**


 Helps platelets stick together and stick to the blood vessel walls when wound is present


## Correlation to PE

 High VWF plasma levels are associated with increased risk of VTI or other related events



# **VWF RESULTS**





N= 87


Ν	=	17	15
			$\sim$

Percentiles (N = 87)	PE patients	Control plasma
25%	129.24	65.24
50%	139.73	57.64
75%	146.66	84.02


Percentiles (N = 115)	PE patients	Control plasma
25%	129.06	43.64
50%	140.56	67.10
75%	149.60	84.07 THROMBOS



# **VWF RESULTS**



N= 87



N= 115






# ENDOGENOUS GAGS ANALYSIS





## **BACKGROUND ON ENDOGENOUS GAGS**



#### Structure

 Specific group of glycoprotein made in Golgi Apparatus

#### **Function**


 Widespread throughout body, including the cell signaling process


#### Correlation to PE

Increased thrombo-inflammatory response associated with endogenous GAGS



# **ENDOGENOUS GAGS RESULTS**





N	=	11	15


Percentiles (N = 87)	PE patients	Control plasma
25%	0.62	0.06
50%	1.83	0.42
75%	3.29	1.21


Percentiles (N = 115)	PE patients	Control plasma
25%	0.81	0.08
50%	1.36	0.64
75%	2.50	1.26 AROMBO





# **ENDOGENOUS GAGS RESULTS**











## **CROSS ANALYSIS**





# **HEAT MAP RESULTS**







1.0


0.5

0

-0.5



# **FOLD INCREASE COMPARISON**







# **LIMITATIONS**

In order to understand the complexity of glycemic control and other factors, we would have needed to do subgroup analyses and also needed a higher patient group population





# CONCLUSION

- Our hypothesis was proven correct since there was a difference between the control and diabetic PE patient biomarker levels and some biomarkers had positive correlations between the two
- Further investigation is needed for a larger data set and understanding the role of glycemic control





# **NEXT STEPS**

- submit abstract to ASH meeting
- submit abstract to FASEB
- possibly visit Loyola in October





# **ACKNOWLEDGEMENT**

 I would like to thank Dr. Laddu, Dr. BK, Dr. Fareed, the Loyola staff, and GTF team for helping aid me during this project.





# THANK YOU!

DO YOU HAVE ANY QUESTIONS?



